Document is current
Any future updates will be listed below
-
Authors
Lübke, Johannes
Metzgeroth, Georgia
Reiter, Andreas
Schwaab, Juliana
-
Funding
Funding for this research was provided by:
Wilhelm Sander-Stiftung (2023.120.1)
Wilhelm Sander-Stiftung (2023.120.1)
Wilhelm Sander-Stiftung (2023.120.1)
Medizinische Fakultät Mannheim der Universität Heidelberg
- License Information
-
More Information
Article History
Accepted: 2 July 2024
First Online: 22 July 2024
Declarations
:
: JL and GM declare no competing interest. AR received consulting fees, honoraria and research funding from Abbvie, AOP Orphan Pharmaceuticals, Blueprint Medicines Corporation, BMS, GlaxoSmithKline, Incyte and Novartis and was member on an entity's Board of Directors or advisory committees of Abbvie, AOP Orphan Pharmaceuticals, Blueprint Medicines, BMS, GSK, Incyte and Novartis. JS received consulting fees from Blueprint Medicines, Astra Zeneca and GlaxoSmithKline, honoraria from Blueprint Medicines, GlaxoSmithKline and Novartis and research funding from GlaxoSmithKline, Blueprint Medicines and Cogent.
: JL and GM declare no competing interest. AR received consulting fees, honoraria and research funding from Abbvie, AOP Orphan Pharmaceuticals, Blueprint Medicines Corporation, BMS, GlaxoSmithKline, Incyte and Novartis and was member on an entity's Board of Directors or advisory committees of Abbvie, AOP Orphan Pharmaceuticals, Blueprint Medicines, BMS, GSK, Incyte and Novartis. JS received consulting fees from Blueprint Medicines, Astra Zeneca and GlaxoSmithKline, honoraria from Blueprint Medicines, GlaxoSmithKline and Novartis and research funding from GlaxoSmithKline, Blueprint Medicines and Cogent.
